Insider Selling: Avalo Therapeutics (NASDAQ:AVTX) Insider Sells $20,000.00 in Stock

Avalo Therapeutics, Inc. (NASDAQ:AVTX) insider Mittie Doyle sold 1,000 shares of the business’s stock in a transaction on Monday, July 27th. The shares were sold at an average price of $20.00, for a total transaction of $20,000.00. Following the sale, the insider owned 51,776 shares of the company’s stock, valued at $1,035,520. This trade represents a 1.89% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Mittie Doyle also recently made the following trade(s):

• On Tuesday, June 23rd, Mittie Doyle sold 1,450 shares of Avalo Therapeutics stock. The stock was sold at an average price of $18.00, for a total transaction of $26,100.00.

Avalo Therapeutics Stock Performance

Shares of Avalo Therapeutics stock traded down $0.51 during trading hours on Wednesday, reaching $19.01. The company’s stock had a trading volume of 789,785 shares, compared to its average volume of 1,216,428. Avalo Therapeutics, Inc. has a one year low of $6.51 and a one year high of $24.27. The company has a market capitalization of $1.01 billion, a P/E ratio of -3.48 and a beta of 0.78. The stock’s fifty day simple moving average is $16.87 and its two-hundred day simple moving average is $16.16.

Avalo Therapeutics (NASDAQ:AVTX) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($0.98) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.00) by $0.02. As a group, research analysts forecast that Avalo Therapeutics, Inc. will post -2.58 earnings per share for the current year.

Wall Street Analysts Forecast Growth

AVTX has been the subject of several analyst reports. BTIG Research reissued a “buy” rating and issued a $58.00 price objective on shares of Avalo Therapeutics in a research note on Tuesday, June 16th. Mizuho upped their price target on Avalo Therapeutics from $39.00 to $45.00 and gave the stock an “outperform” rating in a report on Thursday, May 14th. Cantor Fitzgerald reissued an “overweight” rating on shares of Avalo Therapeutics in a research report on Friday, July 24th. Bank of America began coverage on Avalo Therapeutics in a research note on Friday, June 12th. They set a “buy” rating and a $35.00 price objective on the stock. Finally, Wedbush cut their price objective on shares of Avalo Therapeutics from $40.00 to $34.00 and set an “outperform” rating on the stock in a report on Thursday, May 14th. Thirteen research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Avalo Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $45.80.

Institutional Investors Weigh In On Avalo Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in AVTX. PFS Partners LLC lifted its position in shares of Avalo Therapeutics by 100.0% during the 4th quarter. PFS Partners LLC now owns 2,000 shares of the company’s stock worth $36,000 after buying an additional 1,000 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Avalo Therapeutics by 2.5% in the second quarter. Geode Capital Management LLC now owns 110,460 shares of the company’s stock valued at $552,000 after acquiring an additional 2,648 shares in the last quarter. Glenmede Trust Co. NA increased its position in shares of Avalo Therapeutics by 25.8% during the first quarter. Glenmede Trust Co. NA now owns 25,730 shares of the company’s stock valued at $384,000 after acquiring an additional 5,280 shares during the last quarter. Dimensional Fund Advisors LP purchased a new stake in shares of Avalo Therapeutics during the third quarter valued at approximately $143,000. Finally, Boothbay Fund Management LLC purchased a new stake in shares of Avalo Therapeutics during the second quarter valued at approximately $56,000. Hedge funds and other institutional investors own 87.06% of the company’s stock.

Avalo Therapeutics Company Profile

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.